PRA Health Sciences expands its response to COVID-19 with pharmacovigilance solutions for authorized vaccines and therapeutics
PRA offers post-authorization safety solutions to keep up with the speed of COVID-19 vaccine and therapeutic pharmacovigilance requirements
RALEIGH, N.C., April 21, 2021 (GLOBE NEWSWIRE) PRA Health Sciences (NASDAQ: PRAH) announced today the expansion of its pharmacovigilance solution to offer full post-marketing services for authorized COVID-19 vaccines and therapeutics, including post-authorization safety studies (PASS) delivered by Real World Solutions. With more than 25 years of experience executing comprehensive pharmacovigilance and patient safety services in all key therapeutic areas including infectious diseases, PRA can work closely with drug developers and manufacturers in ensuring long-term safety and efficacy of COVID-19 vaccines and treatments.
PRA Health Sciences seleccionada por Maryland State Medical Society para ofrecer servicios de telesalud y monitoreo remoto de pacientes
tynmagazine.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tynmagazine.com Daily Mail and Mail on Sunday newspapers.
PRA Health Sciences amplía su respuesta al COVID-19 con soluciones de farmacovigilancia para vacunas y productos terapéuticos autorizados
tynmagazine.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tynmagazine.com Daily Mail and Mail on Sunday newspapers.